Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zaxine | Rifaximin | Hepatic encephalopathy | List with criteria/condition | Complete | ||
| Edurant | Rilpivirine | HIV infection | List | Complete | ||
| Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
| Adempas | Riociguat | Pulmonary arterial hypertension (WHO group 1) | List with clinical criteria and/or conditions | Complete | ||
| Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete |
Last Updated : April 27, 2024